| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Angiotensin II receptor type 1 (AT1R) is the primary target of Olmesartan, the parent drug. Olmesartan lactone impurity is a related substance of Olmesartan. As an impurity, its primary relevance is in analytical chemistry rather than as a pharmacologically active compound. The compound is not typically studied for its pharmacological activity but rather for quality control purposes.
|
|---|---|
| ln Vitro |
In vitro, Olmesartan lactone impurity is a related substance of Olmesartan. As an impurity, its primary relevance is in analytical chemistry rather than as a pharmacologically active compound. Olmesartan itself is a potent and specific AT1 receptor antagonist. The lactone impurity is not typically studied for pharmacological activity.
|
| ln Vivo |
In vivo, Olmesartan demonstrates antihypertensive activity. The lactone impurity is typically not studied for pharmacological activity but rather for quality control purposes. The compound is not administered to animals for pharmacological studies.
|
| Enzyme Assay |
Analytical methods such as HPLC are used to detect and quantify Olmesartan lactone impurity in pharmaceutical formulations. The compound serves as a reference standard for the identification and quantification of the impurity in drug substance and drug product. The analytical methods are validated for specificity, accuracy, precision, and linearity.
|
| Cell Assay |
Cell-based assays are not typically performed for impurities. The compound is used as a reference material in analytical testing. No functional assays are typically performed for Olmesartan lactone impurity.
|
| Animal Protocol |
In vivo studies are not typically performed for impurities. The compound is used as a reference standard in pharmaceutical quality control. No animal studies are typically performed for Olmesartan lactone impurity.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Olmesartan lactone impurity are not typically studied. Olmesartan itself is the active pharmaceutical ingredient with well-characterized PK. The impurity is not administered to humans or animals for pharmacokinetic studies.
|
| Toxicity/Toxicokinetics |
Toxicology data for Olmesartan lactone impurity are evaluated as part of pharmaceutical impurity profiling to ensure safety at trace levels in drug products. The impurity is present at low levels in Olmesartan-containing products, and its safety is assessed based on its concentration and toxicological profile. The compound is not administered as a therapeutic agent.
|
| References |
|
| Additional Infomation |
Olmesartan lactone impurity (CAS: 849206-43-5) is a reference standard used in the quality control of Olmesartan-containing pharmaceutical products. The compound is also known as Olmesartan Medoxomil - Impurity B. Olmesartan lactone impurity has a molecular formula of C24H24N6O2 and a molecular weight of 428.49. The compound is not a therapeutic agent and is not approved for human use. The compound is intended for research and quality control purposes only.
|
| Molecular Formula |
C24H24N6O2
|
|---|---|
| Molecular Weight |
428.49
|
| Exact Mass |
428.196
|
| CAS # |
849206-43-5
|
| PubChem CID |
71751323
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.136
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
32
|
| Complexity |
667
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)OC2(C)C
|
| InChi Key |
JUQNVWFXORBZQJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H24N6O2/c1-4-7-19-25-21-20(23(31)32-24(21,2)3)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13H,4,7,14H2,1-3H3,(H,26,27,28,29)
|
| Chemical Name |
6,6-dimethyl-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]furo[3,4-d]imidazol-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3338 mL | 11.6689 mL | 23.3378 mL | |
| 5 mM | 0.4668 mL | 2.3338 mL | 4.6676 mL | |
| 10 mM | 0.2334 mL | 1.1669 mL | 2.3338 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
